

Anti-CLDN18.2 Reference Antibody (osemitamab)

Catalog # APR11247

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P56856
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	27856


Additional Information

Target/Specificity	CLDN18.2
Expression system	CHO


Protein Information

Name	CLDN18
Function	Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription (By similarity). Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency (By similarity). Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways (By similarity).
Cellular Location	Cell junction, tight junction {ECO:0000250 UniProtKB:P56857}. Cell membrane {ECO:0000250 UniProtKB:P56857}; Multi-pass membrane protein. Note=Localizes to tight junctions in epithelial cells {ECO:0000250 UniProtKB:P56857} [Isoform A2]: Cell junction, tight junction {ECO:0000250 UniProtKB:P56857}. Lateral cell membrane {ECO:0000250 UniProtKB:P56857}
Tissue Location	[Isoform A1]: Expression is restricted to the lung.


Images



Anti-CLDN18.2 Reference Antibody (osemitamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-CLDN18.2 Reference Antibody (osemitamab) is 99.4%, determined by SEC-HPLC.



Human 18.2-HEK293 cells at 1E5 cell/well were stained with osemitamab and negative control protein respectively, washed and then followed by PE and analyzed with FACS, with the EC50 is 2.134 nM.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.